UB Paderborn / Katalog / Suche / in CDI

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

The Lancet (British edition), 2007-02, Vol.369 (9561), p.559-570

2007

Volltextzugriff (PDF)

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

Annals of oncology, 2011-10, Vol.22 (10), p.2201-2207

2011

Volltextzugriff (PDF)

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

Annals of oncology, 2009-09, Vol.20 (9), p.1489-1498

2009

Volltextzugriff (PDF)

Conventional rotational molding process and aerodynamic characteristics of an axial-flow hollow blades rotor

International journal of advanced manufacturing technology, 2019-09, Vol.104 (1-4), p.1183-1194

2019

Volltextzugriff (PDF)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

British journal of cancer, 2012-11, Vol.107 (10), p.1665-1671

2012

Volltextzugriff (PDF)

A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative

Annals of oncology, 2013-01, Vol.24 (1), p.47-53

2013

Volltextzugriff (PDF)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

British journal of cancer, 2013-03, Vol.108 (4), p.887-900

2013

Volltextzugriff (PDF)

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)

Annals of oncology, 2013-06, Vol.24 (6), p.1513-1525

2013

Volltextzugriff (PDF)

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

Annals of oncology, 2003-09, Vol.14 (9), p.1391-1398

2003

Volltextzugriff (PDF)

A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI

Breast cancer research and treatment, 2014-07, Vol.146 (1), p.109-116

2014

Volltextzugriff (PDF)

Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.189-196

2018

Volltextzugriff (PDF)

Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs

Breast cancer research and treatment, 2011-10, Vol.129 (3), p.767-776

2011

Volltextzugriff (PDF)

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

Journal of clinical oncology, 2000-02, Vol.18 (4), p.724-733

2000

Volltextzugriff (PDF)

Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up

Annals of oncology, 2012-06, Vol.23 (6), p.1449-1454

2012

Volltextzugriff (PDF)

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)

Annals of oncology, 2007-01, Vol.18 (1), p.64-69

2007

Volltextzugriff (PDF)

Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer

Clinical genetics, 2008-03, Vol.73 (3), p.197-211

2008

Volltextzugriff (PDF)

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

Journal of clinical pathology, 2005-06, Vol.58 (6), p.611-616

2005

Volltextzugriff (PDF)

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel

Breast cancer research and treatment, 2014-10, Vol.147 (3), p.557-570

2014

Volltextzugriff (PDF)

Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data

Annals of oncology, 2013-02, Vol.24 (2), p.350-355

2013

Volltextzugriff (PDF)

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

Annals of oncology, 2007-05, Vol.18 (5), p.859-867

2007

Volltextzugriff (PDF)

E12. Managing toxicity of aromatase inhibitors in early breast cancer

European journal of cancer (1990), 2012-03, Vol.48, p.S26-S27

2012

Volltextzugriff (PDF)

The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen

Annals of oncology, 2014-01, Vol.25 (1), p.90-95

2014

Volltextzugriff (PDF)

Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis

Annals of oncology, 2011-08, Vol.22 (8), p.1763-1769

2011

Volltextzugriff (PDF)

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

Breast cancer research and treatment, 2010-09, Vol.123 (2), p.463-469

2010

Volltextzugriff (PDF)

Investigation on the generation mechanisms of acoustic streaming in a thermoacoustic prime mover

Cryogenics (Guildford), 2013-12, Vol.58, p.78-84

2013

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

Conventional rotational molding process and aerodynamic characteristics of an axial-flow hollow blades rotor

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI

Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study

Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)

Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel

Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

E12. Managing toxicity of aromatase inhibitors in early breast cancer

The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen

Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

Investigation on the generation mechanisms of acoustic streaming in a thermoacoustic prime mover

Suchergebnisse filtern